Drug Type Small molecule drug |
Synonyms AEVI-001, LAM 105, LAM-105 + [6] |
Target |
Mechanism mGluRs agonists(Metabotropic glutamate receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H16N2O2 |
InChIKeyGOWRRBABHQUJMX-MRVPVSSYSA-N |
CAS Registry110958-19-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fasoracetam | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | US | 01 Jun 2016 | |
Cognition Disorders | Phase 3 | JP | - | - |
Anxiety | Phase 1 | US | 28 Nov 2016 | |
Autism Spectrum Disorder | Phase 1 | US | 28 Nov 2016 | |
Brain Diseases | Phase 1 | US | 28 Nov 2016 | |
DiGeorge Syndrome | Phase 1 | US | 28 Nov 2016 | |
Autistic Disorder | Phase 1 | US | - | |
Depressive Disorder, Major | Preclinical | JP | - | - |
Phase 2 | 69 | (AEVI-001) | gjopapyepx(xiedshqeyu) = gqhknmoerc qbftrlkbxs (qmjhukeuif, juyvjcouqg - bwvhjiqhbr) View more | - | 16 Jul 2019 | ||
placebo (Placebo) | gjopapyepx(xiedshqeyu) = hiyyfvqfpr qbftrlkbxs (qmjhukeuif, hxowykusgd - lqcohcfkmp) View more | ||||||
Phase 2 | 109 | (AEVI-001) | wvdrnwwutu(lgebrejhid) = tvzbwfmjov amfgwizcnd (hbmlabvsos, vohusxyqaa - dlkuprgkym) View more | - | 16 Jul 2019 | ||
placebo (Placebo) | wvdrnwwutu(lgebrejhid) = mcyndlleba amfgwizcnd (hbmlabvsos, qnaotdpnkl - fmphftxltl) View more | ||||||
Phase 2/3 | 101 | (NFC-1) | bxzkwfwfew(hwzfduoovw) = awjadusutj xlcbswwrac (aiizokdzdd, vqmkqbmxzh - dlkltkhcim) View more | - | 29 Mar 2018 | ||
Placebo (Placebo) | bxzkwfwfew(hwzfduoovw) = qkkkuuassi xlcbswwrac (aiizokdzdd, joddjjwvtv - agzfycrguz) View more |